Holen Sie sich die Stockscreener-App
0.8199
8.90%
-0.0801
Schlusskurs vom Vortag:
$0.90
Offen:
$0.9
24-Stunden-Volumen:
480.67K
Relative Volume:
0.80
Marktkapitalisierung:
$85.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.73M
KGV:
-6.3069
EPS:
-0.13
Netto-Cashflow:
$-3.92M
1W Leistung:
+3.52%
1M Leistung:
+11.64%
6M Leistung:
-34.93%
1J Leistung:
+55.99%
1-Tages-Spanne:
$0.81
$0.905
1-Wochen-Bereich:
$0.7651
$0.9399
52-Wochen-Spanne:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Firmenname
Tiziana Life Sciences Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.8199 | 85.12M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2018-12-17 | Eingeleitet | Laidlaw | Buy |
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
Tiziana Life Sciences Announces Agreement With Renaissance Lakewood -February 21, 2025 at 10:50 am EST - Marketscreener.com
Tiziana Life Sciences & Renaissance Partner on Nasal Foralumab Production - Contract Pharma
Tiziana Life Sciences Teams Up With Renaissance Lakewood on Nasal Drug Delivery - Marketscreener.com
Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership - Proactive Investors UK
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC - The Manila Times
Tiziana Life Sciences Partners with Renaissance Lakewood to Advance Development of Intranasal Foralumab for Neurodegenerative Diseases - Nasdaq
Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program - Proactive Investors UK
Breakthrough MS Treatment Shows Promise: 100% Patient Response Rate in Expanded Trial - StockTitan
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Expands By 128.0% - MarketBeat
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease - GlobeNewswire
Tiziana Life Sciences says foralumab shows promise in Alzheimer’s treatment - Proactive Investors USA
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
Tiziana Life Sciences Faces Nasdaq Compliance Challenge - MSN
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4% - Defense World
Tiziana Life Sciences (FRA:0RP) Total Liabilities : €8.46 Mil (As of Jun. 2024) - GuruFocus.com
Tiziana reports progress in spinal cord injury treatment - MSN
Tiziana Life Sciences Ltd (NASDAQ: TLSA) Jumps 11.06%: What Could Be On The Way Going Forward? - Stocks Register
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 - The Manila Times
Tiziana reports progress in spinal cord injury treatment By Investing.com - Investing.com Australia
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury - Proactive financial news
Tiziana's Nasal Treatment Shows Promise for Spinal Cord Injury Recovery in Breakthrough Study - StockTitan
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study - Benzinga
Tiziana Life Sciences not to engage in capital raising activities for the immediate future - The Manila Times
Tiziana Life Sciences Halts Capital Raising Plans After Promising MS Treatment Biomarker Discovery - StockTitan
Tiziana Life Sciences pauses capital raising activities - Proactive Investors USA
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab - The Manila Times
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab - Proactive Investors UK
Tiziana Life Sciences Reveals Breakthrough Biomarkers in Multiple Sclerosis Treatment Study - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest - MarketBeat
3 Penny Stocks In US With Market Caps Below $300M - Simply Wall St
Tiziana Life Sciences’ foralumab reduces side effects of discontinuing GLP-1 agonists - Proactive financial news
Tiziana reports progress in immunotherapy treatment - Investing.com India
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 - The Manila Times
Tiziana's Breakthrough Nasal Therapy Enhances GLP-1 Drug Benefits, Reduces Side Effects - StockTitan
Tiziana’s foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Nigeria
Tiziana's foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Canada
Tiziana Life Sciences welcomes publication of article highlighting foralumab’s potential in neurological diseases - Proactive Investors UK
Tiziana's foralumab shows promise in neurodegenerative diseases - Investing.com India
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease - The Manila Times
Tiziana's Foralumab Shows Breakthrough Potential for Multiple Sclerosis in Nature Reviews Study - StockTitan
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus - Benzinga
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest - MarketBeat
Now Is The Time To Build A Position In Tiziana Life Sciences Ltd (NASDAQ:TLSA) - Marketing Sentinel
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis - Seeking Alpha
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):